Avantor's NuSil Expands HIV Prevention Ring Development with Population Council
Event summary
- Avantor's NuSil brand is expanding its partnership with the Population Council to develop a three-month dapivirine vaginal ring for HIV prevention.
- The new ring aims to reduce annual costs and improve accessibility, requiring only four rings per year compared to twelve with the one-month version.
- NuSil's high-purity medical-grade silicones are critical to the ring's design and consistent drug release over the three-month period.
- The Population Council submitted the three-month ring for regulatory review by the European Medicines Agency in November 2025.
The big picture
Avantor's expansion of its partnership with the Population Council underscores a strategic focus on addressing global health challenges through innovative healthcare solutions. The development of the three-month dapivirine vaginal ring aligns with broader industry trends towards long-acting HIV prevention methods, aiming to improve adherence and reduce transmission rates among women in sub-Saharan Africa.
What we're watching
- Regulatory Approval
- The pace at which the three-month dapivirine vaginal ring secures regulatory approvals in sub-Saharan Africa and other regions.
- Market Adoption
- Whether the extended-duration ring can enhance adherence and convenience, leading to broader market adoption.
- Cost Efficiency
- How the reduced annual costs of the three-month ring will impact accessibility and affordability in high HIV prevalence regions.